Briacell Therapeutics CORP. (BCTXZ) — 10-Q Filings
All 10-Q filings from Briacell Therapeutics CORP.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
BriaCell's Q1 Loss Widens 42% on Soaring R&D Costs
— Dec 11, 2025 Risk: high
BriaCell Therapeutics Corp. (BCTXZ) reported a significant increase in net loss for the three months ended October 31, 2025, reaching $8,278,328, up from $5,829 -
BriaCell's Q3 Loss Widens Amid Increased R&D Spend
— Jun 16, 2025 Risk: high
BriaCell Therapeutics Corp. reported no revenue for the three and nine months ended April 30, 2025, consistent with its clinical-stage biotechnology status. The -
BriaCell Therapeutics Files 10-Q for Q1 2025
— Dec 16, 2024 Risk: medium
BriaCell Therapeutics Corp. filed a 10-Q for the period ending October 31, 2024. The company, formerly known as Ansell Capital Corp., reported financial data fo -
BriaCell Therapeutics Files Q3 2024 10-Q
— Jun 14, 2024 Risk: medium
BriaCell Therapeutics Corp. filed its 10-Q for the period ending April 30, 2024. The company reported financial results and operational updates. Key financial f -
BriaCell Therapeutics Corp. Files 10-Q for Period Ending January 31, 2024
— Mar 18, 2024 Risk:
BriaCell Therapeutics Corp. (BCTXZ) filed a Quarterly Report (10-Q) with the SEC on March 18, 2024. BriaCell Therapeutics Corp. filed a 10-Q for the period endi
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX